Key information made simple
This EU CTR study is evaluating BXCL501 for agitation linked to pediatric schizophrenia and bipolarity. The Spanish protocol is listed as restarted, which the app currently maps to ongoing.
OngoingEUCTR 2021-001337-40
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND Bipolarity
This study is ongoing. It focuses on schizophrenia and currently lists study information in Spain.
SchizophreniaOther
Your next step
The public record does not provide enough detail to summarize the visit format or participation steps clearly. Check the official source for the exact eligibility criteria, locations, contact details, and current recruiting status before taking any next step.
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordAsk HopeStage to review this study with me
This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Study reference: EUCTR 2021-001337-40. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
For you
Taking part may help improve understanding of your condition.
It requires a lighter follow-up, often with questionnaires or check-ins.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Things to check before joining
- Sponsor
- BioXcel Therapeutics, Inc.
- Sponsor type
- Biotech company
- Main activity
- digital app or tool
- Time commitment
- multiple visits or assessments
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Ongoing
- Source
- Official registry link
Questions about this study
What is A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND Bipolarity?
This study is exploring digital app or tool for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by BioXcel Therapeutics, Inc.. Based on the sponsor name or official registry information, it appears to be a biotech company. You should verify the details in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve digital app or tool, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.